Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.

Investors Business Daily

FDA says knockoff versions of Lilly obesity drug must come off the market

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes

The Independent UK

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly To Invest $3B To Expand Plant To Meet Surge In Demand For Weight Loss Drugs

Construction on the facility in Kenosha County, Wis., is expected to begin next year.

International Business Times

Eli Lilly Invests Billion In Manufacturing Expansion Projects

Eli Lilly invests billion to boost manufacturing capabilities, expanding in Wisconsin and Indianapolis to meet growing market demand.

Top News

Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products

The Independent UK

The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market

An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Is Zepbound or Wegovy better for weight loss? New clinical trial reveals which medication sheds more pounds

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables.

Fortune

Decoding Eli Lilly's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:LLY).

Benzinga

Eli Lilly stock higher following surprise weight loss treatment data

Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.

The Street

3 Mega-Cap Stocks to Buy Before They're Worth $1 Trillion

These corporate giants could be the next entrants to the $1 trillion market cap club.

Barchart

Behind the Scenes of Eli Lilly's Latest Options Trends

Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 8 unusual trades.

Benzinga

Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert

STOCK RISES OVER 2.8% AT ITS HIGH FOR THE DAY

Benzinga

Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?

Robert F. Kennedy Jr.'s potential appointment to HHS has spooked Eli Lilly stock and stocks tied to popular weight-loss drugs.

Barchart

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

Investors Business Daily

Eli Lilly Option Trade Produces $1,125, If You Can Tolerate The Heavy Risk

A short strangle on Eli Lilly will generate $1,125 in option premium and takes advantage of the current high level of implied volatility.

International Business Times

Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times

Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan

Eli Lilly is taking the HRSA to court for allegedly blocking the pharma's discount plan.

Fortune

Eli Lilly CEO's explains how failing fast leads to success

For Eli Lilly CEO Dave Ricks, speeding up the drug discovery process is essential to success.

Investors Business Daily

Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

Investors Business Daily

Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot

Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral density loss.

Barchart

Eli Lilly Stock: Is Wall Street Bullish or Bearish?

Eli Lilly has outperformed the broader market and its peers this year, and Wall Street analysts are bullish about the stock’s prospects.

The Guardian - UK

Approved weight-loss drug contributed to UK nurse’s death, report says

Susan McGowan took two doses of tirzepatide, under Mounjaro brand, before she died in North Lanarkshire

The National (Scotland)

Scottish nurse’s death linked to approved weight-loss drug

THE death of a Scottish nurse has been linked to a weight-loss drug approved on the NHS.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.